Project Grant R21CA292298
Award Date
8/7/24
Completion Date
7/31/26
Dollars Obligated
$396K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Kansas City, MO 64108, USA
Similar Awards
This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to discover and validate CYP8B1 inhibitors as potential treatments for hepatocellular carcinoma (HCC). The project aims to: 1) identify CYP8B1 inhibitors through high-throughput screening of a 250,000-compound library; 2) validate hit compounds for potency, specificity, and structure-activity relationships; and 3)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted Aurora-A kinase (AURKA) inhibitor, NN-01-195. The goal is to establish the mechanism of action for NN-01-195 and evaluate its in vivo tumor accumulation and efficacy, benchmarking it against two parental compounds - the AURKA inhibitor TAS-119 and the HSP90 inhibitor SNX-2112. The...
This federal Project Grant award of $267,298 from the National Cancer Institute (NCI) under CFDA 93.395 - Cancer Treatment Research supports research aimed at targeting the CDK4/6 pathway in translocation renal cell carcinoma (TRCC), an aggressive and difficult-to-treat form of kidney cancer. The primary goals of this 2-year award, which runs from February 2025 to January 2027, are to evaluate the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR...
The National Cancer Institute (NCI) awarded a $371,905 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Florida to support research on the role of Angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (CCRCC). The project aims to define ANGPTL4's functions in the CCRCC tumor microenvironment, evaluate the efficacy of combining anti-ANGPTL4 antibodies with immune checkpoint inhibitors in mouse models, and determine ANGPTL4's cancer...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is supporting research to develop novel inhibitors of the CYP8B1 protein, which plays a key role in the development of obesity-associated hepatocellular carcinoma (HCC). The $213,284 award to the Beckman Research Institute of the City of Hope will fund two aims: 1) Determining the role of CYP8B1 in obesity-associated HCC using mouse models, and 2) Performing chemical modifications and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,349 to The University of Texas Southwestern Medical Center to investigate the molecular mechanisms by which the Von Hippel-Lindau (VHL) tumor suppressor regulates gene expression via N6-methyladenosine (m6A) modification in clear cell renal cell carcinoma (ccRCC). The research aims to determine how VHL interacts with the m6A enzymatic complex to control m6A-dependent gene expression,...
The National Cancer Institute (NCI) awarded a $230,711 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Trustees of Columbia University in the City of New York to conduct research on overcoming resistance to Hedgehog inhibition in basal cell carcinomas. The 2-year project aims to elucidate the role of the BRD9 chromatin remodeling protein in promoting an immunosuppressive tumor microenvironment, and to evaluate the potential of combining BRD9 blockade with immune...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $927,997 to Lagrange Scientific LLC to develop a prognostic assay for metastatic clear cell renal cell carcinoma (cCRCC). The goal is to identify a panel of metabolite biomarkers that can accurately predict early disease progression to metastasis in cCRCC patients, enabling earlier initiation of systemic therapy for aggressive subtypes. The project will utilize...